BOZEMAN, Mont., Jan. 3 /PRNewswire/ -- LigoCyte Pharmaceuticals Inc.
announces that its Board of Directors has appointed Donald P. Beeman as
Chairman of the Board. Mr. Beeman has been the chief executive officer at
LigoCyte since May of 2006. Mr. Beeman succeeds William G. Little who has
served as the chairman since 2005.
"LigoCyte has continued to advance as a clinical development company
with the strong and seasoned leadership of Don Beeman. It is with great
pleasure and confidence that the board recognizes Don's effectiveness and
acknowledges his ability to lead the company through the next stages of
growth in the coming years," said Mr. Little.
It is with great honor that I accept this position. I look forward to
having our first compound in the clinic early this year," said Donald
Beeman. Most recently the president and co-founder of Topaz Pharmaceuticals
LLC, Mr. Beeman has over 25 years experience in top executive positions in
the pharmaceutical industry. Before joining Topaz Pharmaceuticals, Mr.
Beeman was the vice president of U.S. commercial operations for Merck's
Vaccine Division. Mr. Beeman established a strong leadership reputation at
Merck, having held executive positions in both the U.S. and Australia.
Mr. Little, the former chairman and retired CEO of West Pharmaceuticals
Services, continues on LigoCyte's Board assuming the responsibility of lead
independent director and chairman of the governance and nominating
committee. Also on the Board: Mr. Mark McDade, the CEO of PDL BioPharma,
Inc. (Nasdaq: PDLI); Mr. Jon Marchi, the chairman of Glacier Venture Fund
and the Development Corporation of Montana; Dr. Robert F. Bargatze, the
chief scientific officer and founder of LigoCyte; Dr. J. Donald deBethizy,
the president and CEO of Targacept, Inc. (Nasdaq: TRGT); Dr. John W.
Jutila, the retired vice president of research at Montana State University
and founder of LigoCyte; Mr. John Tomlin, a founding partner of The Vista
Group; and Mr. Scott Warwood, the Montana general manager of Johnson
Controls, Inc. (NYSE: JCI).
About LigoCyte:
LigoCyte, established in 1998, is developing a new generation of
vaccines and monoclonal antibody therapeutics. The company is planning
clinical testing of its Norovirus vaccine early in 2007 to address critical
outbreaks of viral gastroenteritis in hospitals and long-term care
facilities. LigoCyte's proprietary vaccine technologies and unique
monoclonal antibody targets are positioning the company for continued
growth and success in the biotechnology industry. For additional
information on LigoCyte, please visit http://www.ligocyte.com.
Binding Science. Better Medicine.
SOURCE LigoCyte Pharmaceuticals Inc.
 back to top
Related links:
http://www.ligocyte.com/
CONTACT:
Karen Sipes, Ph.D., Director, Marketing &
Communications of LigoCyte Pharmaceuticals, Inc.,
+1-406-556-9228, karen.sipes@ligocyte.com
|
